Vaccines for COVID-19: Where do we stand in 2021?

被引:61
|
作者
Sharma, Ketaki [1 ,2 ]
Koirala, Archana [1 ,2 ,3 ]
Nicolopoulos, Katrina [1 ]
Chiu, Clayton [1 ,2 ]
Wood, Nicholas [1 ,2 ]
Britton, Philip N. [2 ,4 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Nepean Hosp, Dept Infect Dis, Penrith, NSW, Australia
[4] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW, Australia
关键词
COVID-19; SARS-CoV-2; Vaccines; vaccines; NCOV-19; AZD1222; VACCINE; EFFICACY; BNT162B2; SCOTLAND; RISK;
D O I
10.1016/j.prrv.2021.07.001
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARSCoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [31] Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
    Esposito, Renata
    Mirra, Davida
    Sportiello, Liberata
    Spaziano, Giuseppe
    D'Agostino, Bruno
    BIOMEDICINES, 2022, 10 (11)
  • [32] Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?
    Daoud, Ahmed
    Alqassieh, Ahmad
    Alkhader, Duaa
    Posadas Salas, Maria Aurora
    Rao, Vinaya
    Fulop, Tibor
    Soliman, Karim M.
    RENAL FAILURE, 2021, 43 (01) : 273 - 280
  • [33] Schistosomiasis vaccines: where do we stand?
    Tebeje, Biniam Mathewos
    Harvie, Marina
    You, Hong
    Loukas, Alex
    McManus, Donald P.
    PARASITES & VECTORS, 2016, 9 : 1 - 15
  • [34] Schistosomiasis vaccines: where do we stand?
    Biniam Mathewos Tebeje
    Marina Harvie
    Hong You
    Alex Loukas
    Donald P. McManus
    Parasites & Vectors, 9
  • [35] Mucosal Vaccines: Where Do We Stand?
    Kraehenbuhl, Jean-Pierre
    Neutra, Marian R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (20) : 2609 - 2628
  • [36] Controversy with bromhexine in COVID-19; where we stand
    Tolouian, Ramin
    Mulla, Zuber D.
    IMMUNOPATHOLOGIA PERSA, 2021, 7 (02):
  • [37] Rabies vaccines: where do we stand, where are we heading?
    Kaur, Manpreet
    Garg, Rajni
    Singh, Samer
    Bhatnagar, Rakesh
    EXPERT REVIEW OF VACCINES, 2015, 14 (03) : 369 - 381
  • [38] Learning from SARS and MERS: COVID-19 reinfection where do we stand?
    Al-Tawfiq, Jaffar A.
    Rabaan, Ali A.
    Al-Omari, Awad
    Al Mutair, Abbas
    Al-Qahtani, Manaf
    Tirupathi, Raghavendra
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2021, 41
  • [39] Emergency department-based COVID-19 vaccination: Where do we stand?
    Waxman, Michael J.
    Moschella, Phillip
    Duber, Herbert C.
    Martin, Daniel R.
    Benzoni, Thomas
    Rothman, Richard E.
    Schechter-Perkins, Elissa M.
    ACADEMIC EMERGENCY MEDICINE, 2021, 28 (06) : 707 - 709
  • [40] Superadded Coinfections and Antibiotic Resistance in the Context of COVID-19: Where do We stand?
    Kayarat, Bhavana
    Khanna, Puneet
    Sarkar, Soumya
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2021, 25 (06) : 698 - 702